ENCell Co., Ltd. (KOSDAQ:456070)
South Korea · Delayed Price · Currency is KRW 12,300
-170 (-1.36%)
Jul 21, 2025, 2:40 PM KST
ENCell Revenue
ENCell had revenue of 1.09B KRW in the quarter ending March 31, 2025, a decrease of -80.52%. This brings the company's revenue in the last twelve months to 6.51B, down -38.13% year-over-year. In the year 2024, ENCell had annual revenue of 7.21B, down -31.51%.
Revenue (ttm)
6.51B
Revenue Growth
-38.13%
P/S Ratio
20.87
Revenue / Employee
n/a
Employees
n/a
Market Cap
135.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
| Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
| Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
| Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
| Dec 31, 2020 | 1.40B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| Peptron | 4.30B |
| PharmaResearch | 392.31B |